Where Did the Patients Go? Understanding Patient Non-Enrollment in the HOMER Trial on Buprenorphine Treatment for Opioid Use

<h3>Context:</h3> Opioid use disorder (OUD) leads to significant morbidity and overdose death in the United States. The prevalence of OUD has reached epidemic proportions, yet enrolling patients in primary care clinical trials on medication for treatment of OUD (MOUD) can be challenging even under ideal circumstances. <h3>Objective:</h3> Describe factors that appear to be associated with non-enrollment of patients in a comparative effectiveness trial on MOUD induction. <h3>Study Design and Analysis:</h3> Multiple-method analysis using descriptive statistics and iterative ground theory techniques to identify salient themes about patient non-enrollment. <h3>Setting:</h3> Sixty (60) US-based primary care practices from the State Networks of Colorado Ambulatory Practices &amp; Partners and AAFP National Research Network who agreed to participate and enroll patients. <h3>Population studied:</h3> Clinicians and staff perspectives, plus patient enrollment data. <h3>Intervention/Instrument:</h3> Monthly field notes maintained by research staff; de-identified patient tracker data provided by participating clinics. <h3>Outcome measures:</h3> none. <h3>Results:</h3> Reasons for non-enrollment were a combination of patient and clinic factors. Practices understood enrollment criteria, had methods to identify potentially eligible subjects, and were supported by research staff with enrollment strategies. Six of 15 practices that were unable to enroll patients had started new patients on MOUD and offered the HOMER to eligible patients, but without success. Common explanations for non-enrollment were: overall lower-than-expected volume of patients seeking MOUD; patients initiating MOUD outside primary care; patients unwilling to be randomized (preferred a specific induction method), needed immediate treatment (could not wait for randomization), or simply not interested in participating in a study. In several cases where eligible patients were provided enrollment information in HOMER, patients appeared to not follow-up with the study team and next steps in the enrollment process. Practice factors such as clinician absence/turnover and not accepting new OUD patients may have affected patient enrollment. <h3>Conclusion:</h3> Despite the prevalence of OUD in the US, enrollment in a study on MOUD induction proved challenging for some participating primary care practices, likely due to fewer than expected numbers of patients seeking to initiate MOUD in primary care settings and unwillingness from patients and clinicians to be randomized to a study arm.

Authors

Publication Details

Journal
The Annals of Family Medicine
Published
2024-11-20
DOI
https://doi.org/10.1370/afm.22.s1.6656
Primary Topic
Opioid Use Disorder Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Where Did the Patients Go? Understanding Patient Non-Enrollment in the HOMER Trial on Buprenorphine Treatment for Opioid Use

Cory Lutgen, Ben Sofie, Donald E. Nease, John M. Westfall et al.
1 links
The Annals of Family Medicine
Opioid Use Disorder Treatment
article

Where Did the Patients Go? Understanding Patient Non-Enrollment in the HOMER Trial on Buprenorphine Treatment for Opioid Use

Cory Lutgen, Ben Sofie, Donald E. Nease, John M. Westfall, Douglas H. Fernald, Maret Felzien
article en

Abstract

<h3>Context:</h3> Opioid use disorder (OUD) leads to significant morbidity and overdose death in the United States. The prevalence of OUD has reached epidemic proportions, yet enrolling patients in primary care clinical trials on medication for treatment of OUD (MOUD) can be challenging even under ideal circumstances. <h3>Objective:</h3> Describe factors that appear to be associated with non-enrollment of patients in a comparative effectiveness trial on MOUD induction. <h3>Study Design and Analysis:</h3> Multiple-method analysis using descriptive statistics and iterative ground theory techniques to identify salient themes about patient non-enrollment. <h3>Setting:</h3> Sixty (60) US-based primary care practices from the State Networks of Colorado Ambulatory Practices &amp; Partners and AAFP National Research Network who agreed to participate and enroll patients. <h3>Population studied:</h3> Clinicians and staff perspectives, plus patient enrollment data. <h3>Intervention/Instrument:</h3> Monthly field notes maintained by research staff; de-identified patient tracker data provided by participating clinics. <h3>Outcome measures:</h3> none. <h3>Results:</h3> Reasons for non-enrollment were a combination of patient and clinic factors. Practices understood enrollment criteria, had methods to identify potentially eligible subjects, and were supported by research staff with enrollment strategies. Six of 15 practices that were unable to enroll patients had started new patients on MOUD and offered the HOMER to eligible patients, but without success. Common explanations for non-enrollment were: overall lower-than-expected volume of patients seeking MOUD; patients initiating MOUD outside primary care; patients unwilling to be randomized (preferred a specific induction method), needed immediate treatment (could not wait for randomization), or simply not interested in participating in a study. In several cases where eligible patients were provided enrollment information in HOMER, patients appeared to not follow-up with the study team and next steps in the enrollment process. Practice factors such as clinician absence/turnover and not accepting new OUD patients may have affected patient enrollment. <h3>Conclusion:</h3> Despite the prevalence of OUD in the US, enrollment in a study on MOUD induction proved challenging for some participating primary care practices, likely due to fewer than expected numbers of patients seeking to initiate MOUD in primary care settings and unwillingness from patients and clinicians to be randomized to a study arm.

The Annals of Family MedicineVol. 22(Supplement 1)
Openalex Percentile: Top 67%
Opioid Use Disorder Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.